NEW YORK (GenomeWeb) – Luminex today announced it has received a Health Canada Class 3 Device License for the xTAG CYP2D6 kit, a comprehensive in vitro diagnostic assay that analyzes a patient's cytochrome P450 2D6 (CYP2D6) genotype.                              

The test uses DNA extracted from a blood sample and runs on the Luminex 100/200 instrument. Results aid physicians in determining therapeutic strategies for patients who metabolize drugs differently because of the gene product, the firm said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.